<DOC>
	<DOC>NCT00384150</DOC>
	<brief_summary>This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with relapsed or refractory, follicular NHL who demonstrated a response on Study 114-NH-301 with a time-to-progression &gt;=6 months.</brief_summary>
	<brief_title>Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Demonstrated a response (CR, CRu, or PR) on Study 114NH301 (Galiximab in combination with Rituximab compared with Rituximab in combination with Placebo) and then relapsed or progressed with a TTP &gt;=6 months. Relapsed disease is defined as documented disease progression using the International Workshop Response Criteria (IWRC). Bidimensionally measurable disease with at least 1 lesion &gt;=2.0 cm in a single dimension. Acceptable hematologic, hepatic, and renal function. Key Any lymphoma therapy between Final Visit on Study 114NH301 and Study Day 1 of this retreatment study. Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to Study Day 1. Transfusiondependent subjects. Presence of central nervous system (CNS) lymphoma. Histologic transformation. Presence of pleural or peritoneal effusion with positive cytology for lymphoma. Another primary malignancy requiring active treatment. Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions that would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor. New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to Study Day 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>galiximab</keyword>
	<keyword>antibody</keyword>
	<keyword>refractory</keyword>
	<keyword>follicular</keyword>
	<keyword>relapsed</keyword>
	<keyword>NHL</keyword>
	<keyword>rituximab</keyword>
	<keyword>retreatment</keyword>
</DOC>